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Abstract: Estimates of the effect of proton pump inhibitors (PPIs) on risks of upper and lower
gastrointestinal bleeding (UGIB and LGIB) among low-dose aspirin users in routine clinical practice
are variable (UGIB) or lacking (LGIB). We aimed to establish these risks in the same observational
study population. Using UK primary care data, we followed 199,049 new users of low-dose aspirin
(75–300 mg/day) and matched non-users at start of follow-up to identify incident UGIB/LGIB cases.
In nested case–control analyses, adjusted odds ratios (ORs) were calculated for concomitant PPI
use vs. past (discontinued) PPI use among current low-dose aspirin users. For UGIB (n = 987),
ORs (95% CIs) were 0.69 (0.54–0.88) for >1 month PPI use and 2.65 (1.62–4.3) for ≤1 month PPI use.
Among the latter group, ORs (95% CIs) were 3.05 (1.75–5.33) for PPI initiation after start of aspirin
therapy, and 1.66 (0.63–4.36) for PPI initiation on/before start of aspirin therapy. For LGIB (n = 1428),
ORs (95% CIs) were 0.98 (0.81–1.17) for >1 month PPI use and 1.12 (0.73–1.71) for ≤1 month PPI use.
Among low-dose aspirin users, maintaining PPI use (>1 month) was associated with a significantly
reduced UGIB risk. Neither short nor long-term PPI use affected LGIB risk.
Keywords: aspirin; proton pump inhibitors; upper gastrointestinal bleeding; lower gastrointestinal
bleeding
1. Introduction
Low-dose aspirin is widely prescribed for the secondary prevention of cardiovascular disease
(CVD) as this benefit is well established in outweighing the risk of major bleeding [1]. The net value of
low-dose aspirin among individuals without CVD is less certain because of concerns about the risks of
major bleeding [1,2], the most common being that in the gastrointestinal tract. Decisions to prescribe
low-dose aspirin to this patient population in clinical practice, therefore, requires a careful assessment
of individual bleeding risks. Co-administration of an acid-suppressing agent in patients taking
prophylactic low-dose aspirin has been shown to reduce the risk of aspirin-associated gastrointestinal
bleeding [3–7]. Proton pump inhibitors (PPIs) are the preferred agents, being recommended in clinical
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guidelines for use in patients with gastrointestinal risk factors [8–10]. However, the gastroprotective
effects of PPIs are limited to the upper gastrointestinal tract, with no protection against aspirin-induced
bleeding in the lower gastrointestinal tract. Moreover, PPIs have been shown to affect the microbiota
throughout the gastrointestinal tract, but in particular in the lower gastrointestinal tract [11], which
could potentially increase susceptibility to enteric infections and gastrointestinal disorders [11–14].
Small clinical studies have shown that PPIs contribute to injury in the small bowel among low-dose
aspirin users [15,16] yet whether this translates into a higher risk of lower gastrointestinal bleeding
(LGIB) is unclear, as findings from the limited observational data on this topic have been mixed [5,17].
In population-based studies, estimates of the size of a PPI-induced reduction in upper
gastrointestinal bleeding (UGIB) risk among users of low-dose aspirin have varied. Some studies have
had limited power to produce precise estimates of effect, and definitions of drug use between studies
have differed [5–7,18,19]. Further population-based studies are therefore required to quantify the
effects that PPIs have on the risk of both UGIB and LGIB among these patients. Such studies require a
robust study design to minimize threats to internal validity, such as confounding by indication and
confounding arising from differences between users of low-dose aspirin/PPIs in characteristics and
behaviors that are difficult to control for.
We used data from a population-based study of gastrointestinal bleeding set in UK primary
care, using validated cases of both UGIB and LGIB. We used a matched cohort design with nested
case–control analysis to quantify the effect that PPI use (vs. non-use) has on the risk of UGIB and
LGIB among users of low-dose aspirin, using an appropriate reference group for PPI use that aimed to
minimize confounding and selection bias. We analyzed both duration of PPI use (short- or long-term)
and the timing of PPI initiation in relation to the start of low-dose aspirin therapy.
2. Materials and Methods
2.1. Study Design
We used The Health Improvement Network primary care database in the UK, which contains
the electronic health records of approximately 6% of patients across the UK, who collectively are
representative of the UK demographic [20,21]. This population-based database has been shown to be a
valid data source for pharmaco-epidemiological research and for studying low-dose aspirin use in the
UK – unrecorded use of over-the-counter obtained low-dose aspirin in the database has previously
been shown to be minimal [22,23]. Details of our study design, including the study population
inclusion/exclusion criteria, cohort matching, outcome identification and validation, identification
and classification of co-variates, and sampling and frequency matching of controls in the nested
case–control analyses (by age, sex and calendar year), have been published previously [24]. Briefly,
between 1 January, 2000 and December 2012, 199,079 new users of low-dose aspirin and a 1:1 matched
cohort of non-users of low-dose aspirin at the start of follow-up were followed for a maximum of
14 years (mean 5.4 years), and a total of 1843 incident cases of UGIB and 2763 incident cases of LGIB
were identified. In addition to the traditional cohort matching criteria of age and sex, we applied an
additional matching criterion–the number of primary care practitioner (PCP) visits in the year before
start of follow-up. This served as a proxy measurement for general health with the aim of minimizing
confounding from differences between users and non-users of low-dose aspirin at baseline. The index
date was the date of the bleeding event for cases and a random date within their individual observation
period for controls (5000 for UGIB and 10,000 for LGIB). In this present study, to evaluate the effect of
PPI use vs. non-use on UGIB/LGIB risk among low-dose aspirin users, we retained only UGIB/LGIB
cases and controls who were current users of low-dose aspirin (987 UGIB cases, 2160 UGIB controls;
and 1428 LGIB cases, 4100 LGIB controls). All authors had access to the study data and reviewed and
approved the final manuscript.
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2.2. Low-Dose Aspirin and PPI Exposure
Use of low-dose aspirin among UGIB/LGIB cases and controls was categorized as follows: current
use, when the supply of their most recent prescription lasted until (or over) the index date, or ended in
the 30 days before the index date; past (discontinued) use, when low-dose aspirin use ended more
than 1 month before the index date; never use, if there was no recorded low-dose aspirin prescription
before the index date. Within current users of low-dose aspirin, PPI use was categorized using these
same categories.
2.3. Statistical Analyses
Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using unconditional logistic
regression adjusted for confounders using a stepwise forward approach. Patients with missing data
on smoking, body mass index (BMI), alcohol consumption, estimated glomerular filtration rate or
urban/rural residence were placed in a separate category ‘missing’ for that variable The fully adjusted
model for the UGIB outcome was adjusted for the matching variables (sex, age and calendar year)
and number of PCP visits in the year before the index date, alcohol consumption, smoking, history of
UGIB, LGIB, unspecified gastrointestinal bleeding (GIB), peptic ulcer, pancreatic disease, polytherapy
and use of clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs) and warfarin. The fully
adjusted model for the LGIB outcome was adjusted for matching variables (sex, age and calendar
year) and number of PCP visits in the year before the index date, alcohol consumption, smoking, body
mass index, history of polyps, LGIB, unspecified GIB, peptic ulcer, gastro-esophageal reflux disease,
inflammatory bowel disease, irritable bowel syndrome, polytherapy and use of clopidogrel, NSAIDs
and warfarin. Polytherapy was defined as the number of different medications where a prescription
lasted until/over the index date or lasted to within the 30 days before the index date. The main
exposure of interest was current use of low-dose aspirin plus current use of a PPI (i.e., concomitant
use) and, to minimize confounding from time-varying differences between PPI users and non-users
that are difficult to control, the reference group was current use of low-dose aspirin plus past use of
a PPI. To evaluate the likely effect of confounding by indication among individuals who had very
recently started using a PPI (i.e., very short duration of use), we categorized duration of PPI use as
either ≤1 month or >1 month. To explore possible effects relating to the timing of PPI initiation among
low-dose aspirin users, we further categorized PPI use for patients with ≤1 month duration of use
according to whether the PPI was prescribed after the start of low-dose aspirin therapy or on/before
the start of low-dose aspirin therapy. An additional analysis was also undertaken to evaluate the effect
of concomitant PPI use (of any duration vs. past PPI use) among current users of dual antiplatelet
therapy (DAT; low-dose aspirin plus clopidogrel) on the risk of UGIB/LGIB. We did not perform any
analyses for specific PPI agents. All analyses were conducted using STATA version 12.0.
3. Results
3.1. Characteristics of Cases and Controls
The main characteristics of UGIB/LGIB cases and controls are shown in Table 1; further
characteristics can be found in Supplementary Table S1). Among the 987 incident cases of UGIB (all
current users of low-dose aspirin), just over half (56.1%) were male and the mean age was 72.04 years
(median 74 years). Among the 1428 incident cases of LGIB, approximately half were male (51.8%) and
the mean age was 70.26 years (median 71 years).
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n % n % n % n %
Sex
Male 554 56.1 1221 56.5 740 51.8 2116 51.6
Female 433 43.9 939 43.5 688 48.2 1984 48.4
Age (years)
40–59 124 12.6 200 9.3 210 14.7 524 12.8
60–69 245 24.8 495 22.9 414 29.0 1270 31.0
70–79 367 37.2 837 38.8 523 36.6 1528 37.3
80–89 251 25.4 628 29.1 281 19.7 778 19.0
Calendar year
2000–2004 237 24.0 508 23.5 282 19.7 812 19.8
2005–2010 488 49.4 1027 47.5 682 47.8 1957 47.7
2010 and beyond 262 26.5 625 28.9 464 32.5 1331 32.5
Smoking
Non-smoker 351 35.6 850 39.4 562 39.4 1639 40.0
Current 158 16.0 256 11.9 160 11.2 542 13.2
Former 452 45.8 991 45.9 696 48.7 1844 45.0
Missing 26 2.6 63 2.9 10 0.7 75 1.8
BMI (kg/m2)
15–19 51 5.2 71 3.3 53 3.7 118 2.9
20–24 213 21.6 511 23.7 310 21.7 958 23.4
25–29 366 37.1 840 38.9 580 40.6 1526 37.2
≥30 269 27.3 582 26.9 416 29.1 1263 30.8
Missing 88 8.9 156 7.2 69 4.8 235 5.7
Alcohol (u/w)
None 218 22.1 400 18.5 272 19.0 829 20.2
1–9 435 44.1 1070 49.5 731 51.2 1955 47.7
10–20 131 13.3 311 14.4 185 13.0 623 15.2
21–41 62 6.3 94 4.4 78 5.5 202 4.9
≥42 15 1.5 18 0.8 25 1.8 38 0.9
Missing 126 12.8 267 12.4 137 9.6 453 11.0
Polypharmacy
0–1 186 18.8 478 22.1 277 19.4 934 22.8
2–4 258 26.1 658 30.5 412 28.9 1229 30.0
≥5 543 55.0 1024 47.4 739 51.8 1937 47.2
Townsend score
Deprived 1 (least deprived) 34 3.4 55 2.5 40 2.8 103 2.5
Deprived 2 217 22.0 525 24.3 367 25.7 994 24.2
Deprived 3 199 20.2 491 22.7 337 23.6 964 23.5
Deprived 4 198 20.1 440 20.4 286 20.0 833 20.3
Deprived 5 (most deprived) 194 19.7 403 18.7 228 16.0 725 17.7
Missing 145 14.7 246 11.4 170 11.9 481 11.7










n % n % n % n %
Other comorbidities
Myocardial infarction 137 13.9 300 13.9 205 14.4 555 13.5
IHD * 222 22.5 510 23.6 395 27.7 921 22.5
COPD 104 10.5 181 8.4 125 8.8 310 7.6
Hypertension 644 65.2 1482 68.6 947 66.3 2780 67.8
Hyperlipidemia 285 28.9 594 27.5 415 29.1 1241 30.3
Diabetes 267 27.1 563 26.1 308 21.6 1121 27.3
Peptic ulcer,
uncomplicated/complicated 147 14.9 128 5.9 125 8.8 230 5.6
Peptic ulcer, uncomplicated 105 10.6 92 4.3 85 6.0 180 4.4
Peptic ulcer, complicated 64 6.5 46 2.1 54 3.8 67 1.6
IBD 12 1.2 20 0.9 68 4.8 59 1.4
IBS 72 7.3 95 4.4 150 10.5 229 5.6
Dyspepsia 304 30.8 505 23.4 456 31.9 998 24.3
Constipation 224 22.7 345 16.0 300 21.0 574 14.0
GERD 186 18.8 356 16.5 363 25.4 675 16.5
Prior UGIB 30 3.0 18 0.8 23 1.6 35 0.9
Prior LGIB 88 8.9 119 5.5 236 16.5 305 7.4
Prior GIB unspecified 24 2.4 20 0.9 23 1.6 31 0.8
* IHD does not include myocardial infarction. Note: Alcohol, BMI and smoking were ascertained any time before
the index date using the most recent status/value as appropriate. Comorbidities were ascertained any time before
the index date. Polypharmacy was taken as the number of different medications in the month before the index date.
Note: There were 22 (1.5%) cases and 25 (0.6%) controls with a record of melena, and 76 cases (5.3%) and 96 controls
(2.3%) with a record of polyps. Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary
disease; GERD, gastro-esophageal reflux disease; GIB, gastrointestinal bleeding; IBD, inflammatory bowel disease;
IBS, irritable bowel syndrome; IHD, ischemic heart disease; LGIB, lower gastrointestinal bleeding; UGIB, upper
gastrointestinal bleeding; u/w, units per week.
3.2. Effect of PPIs on Risk of UGIB among Low-Dose Aspirin Users
The frequency distribution of low-dose aspirin and PPI use among UGIB cases and controls (all
current users of low-dose aspirin) is shown in Table 2 along with associations between PPI use and
UGIB risk. Among UGIB cases, 265 (26.8%) were concomitant users of a PPI. Among UGIB controls,
489 (22.6%) were concomitant users of a PPI. Compared with the reference group, concomitant current
use of low-dose aspirin and a PPI was associated with a 31% reduced risk of UGIB when the PPI was
used for more than 1 month (OR 0.69, 95% CI: 0.54–0.88) (with estimates similar in analyses stratified
by primary/secondary CVD prevention population; see Supplementary Table S2 for results of this
post-hoc analysis), but with more than a two-fold increased risk during the first month of PPI use (OR
2.65, 95% CI: 1.62–4.33). When analyzing this further, there was no evidence of a significant increase in
UGIB risk when the PPI therapy was initiated on or before the start of low-dose aspirin therapy (OR
1.66, 95% CI: 0.63–4.36), but when the PPI was prescribed after the start of low-dose aspirin therapy,
the increase in risk during the first month of PPI treatment was evident (OR 3.05, 95% CI: 1.75–5.33)
(Table 1). Among current users of DAT, the data were suggestive of a substantial reduction in UGIB risk
(OR 0.62, 95% CI: 0.31–1.25) among patients who had used a PPI concomitantly; however, evaluations
were limited by the small number of patients in the analyses (Supplementary Table S3).
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Table 2. ORs (95 CIs) for the association between concomitant use of low-dose aspirin and a PPI and











Current use of low-dose aspirin and past
use of a PPI (reference group) 223 (22.6) 423 (19.6)
1.0
(reference) 1.0 (reference)
Current use of low-dose aspirin and





Current use of low-dose aspirin and a PPI:





Current use of low-dose aspirin and a PPI:
≤1 month PPI duration and prescribed
after the start of low-dose aspirin
46 (4.7) 22 (1.0) 3.97(2.33–6.76)
3.05
(1.75–5.33)
Current use of low-dose aspirin and a PPI:
≤1 month PPI duration and prescribed
on/before the start of low-dose aspirin
10 (1.0) 9 (0.4) 2.11(0.84–5.20)
1.66
(0.63–4.36)
Current use of low-dose aspirin and a PPI:





Current use of low-dose aspirin and a PPI:
>1 month PPI duration and prescribed after
the start of low-dose aspirin
89 (9.0) 222 (10.3) 0.76(0.57–1.02)
0.63
(0.46–0.86)
Current use of low-dose aspirin and a PPI:
>1 month PPI duration and prescribed
on/before the start of low-dose aspirin
120 (12.2) 236 (10.9) 0.96(0.73–1.27)
0.75
(0.56–1.00)
Current use of low-dose aspirin and never





* Adjusted by matching variables (sex, age and calendar year) and number of PCP visits in the year before the index
date, alcohol consumption, smoking, history of UGIB, LGIB, GIB, peptic ulcer, pancreatic disease, polytherapy and
use of clopidogrel, NSAIDs and warfarin. Abbreviations: CI, confidence interval; GIB, gastrointestinal bleeding;
LGIB, lower gastrointestinal bleeding; NSAID, non-steroidal anti-inflammatory drug; OR, odds ratio; PCP, primary
care practitioner; PPI, proton pump inhibitor; UGIB, upper gastrointestinal bleeding.
3.3. Effect of PPIs on Risk of LGIB among Low-Dose Aspirin Users
The frequency distribution of PPI use among LGIB cases and controls (all current users of low-dose
aspirin) is shown in Table 3 along with associations between PPI use and LGIB risk. Among LGIB cases,
444 (31.1%) were concomitant users of a PPI. Among LGIB controls, 934 (23.4%) were concomitant
users of a PPI. Compared with the reference group, concomitant current use of low-dose aspirin and a
PPI was not associated with a change in LGIB risk when PPI use was greater than 1 month in duration
(OR 0.98, 95% CI: 0.81–1.17) or when PPI use was used for 1 month or less (OR 1.12, 95% CI: 0.73–1.71).
Among the latter, the lack of association was still evident irrespective of when PPI use was initiated in
relation to the start of low-dose aspirin therapy. Among current users of DAT, there was no evidence of
a change in LGIB risk among patients who had used a PPI concomitantly (OR 0.97, 95% CI: 0.39–2.42)
based on the small number of patients in this analysis (Supplementary Table S4).
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Table 3. ORs (95 CIs) for the association between concomitant use of low-dose aspirin and a PPI and











Current use of low-dose aspirin and past use
of a PPI (reference group) 349 (24.4) 833 (20.3)
1.0
(reference) 1.0 (reference)
Current use of low-dose aspirin and current





Current use of low-dose aspirin and a PPI: ≤1





Current use of low-dose aspirin and a PPI: ≤1
month PPI duration and prescribed after the
start of low-dose aspirin
31 (2.2) 58 (1.4) 1.28(0.34–0.47)
1.16
(0.73–1.84)
Current use of low-dose aspirin and a PPI: ≤1
month PPI duration and prescribed on/before
the start of low-dose aspirin therapy
7 (0.5) 15 (0.4) 1.11(0.45–2.76)
0.97
(0.38–2.53)
Current use of low-dose aspirin and a PPI: >1





Current use of low-dose aspirin and a PPI: >1
month PPI duration and prescribed after the
start of low-dose aspirin
192 (13.4) 389 (9.5) 1.18(0.95–1.46)
1.05
(0.84–1.32)
Current use of low-dose aspirin and a PPI: >1
month PPI duration and prescribed on/before
the start of low-dose aspirin therapy
214 (15.0) 499 (12.2) 1.02(0.84–1.25)
0.91
(0.84–1.32)
Current use of low-dose aspirin and never use





* Adjusted by matching variables (sex, age and calendar year) and number of PCP visits in the year before the index
date, alcohol consumption, smoking, BMI, history of polyps, LGIB, unspecified GIB, peptic ulcer, GERD, IBD, IBS,
polytherapy and use of clopidogrel, NSAIDs and warfarin. Abbreviations: BMI, body mass index; CI, confidence
interval; GERD, gastro-esophageal reflux disease; GIB, gastrointestinal bleeding; IBD, inflammatory bowel disease;
IBS, irritable bowel syndrome; LGIB, lower gastrointestinal bleeding, NSAID, non-steroidal anti-inflammatory drug;
OR, odds ratio; PCP, primary care practitioner; PPI, proton pump inhibitor; UGIB, upper gastrointestinal bleeding.
Owing to the fact that the majority of LGIB cases among low-dose aspirin users in UK primary
care are referred to a specialist but not hospitalized (25), we performed a post-hoc analysis in which
we repeated the main LGIB analysis according to whether LGIB cases were only referred (less severe
cases) or were hospitalized (more severe cases). Odds ratios did not differ between these two groups
of cases, with minimal change seen from the main estimate: OR 0.97 (95% CI: 79–1.18) for only referred
cases, and 1.04 (95% CI: 0.78–1.39) for hospitalized cases.
4. Discussion
In our large population-based study, we have shown that among patients using low-dose aspirin
for CVD prophylaxis, those who continued with PPI co-therapy for at least 1 month had a significant
31% reduced risk of UGIB compared with those who discontinued PPI use (past users). However,
co-therapy with a PPI, whether in the short-term or long-term, had no effect on their risk of LGIB. The
increased UGIB risk seen in our study soon after the start of PPI co-therapy (i.e., among patients who
had less than a month of PPI use) is most likely explained by protopathic bias due to the prescription
of PPIs to treat prodromic symptoms of UGIB. Although interpreting the true effect of short-term
PPI use is challenging in a non-randomized setting, results of our analyses separating out the timing
of PPI initiation will help to elucidate the likely true effects of PPI co-prescription among low-dose
aspirin users that are otherwise difficult to infer in observational studies when PPI use is grouped as
single category.
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Our study provides valuable data on the effect that PPIs have on LGIB risk in low-dose aspirin
users because previous data on this topic have been limited and findings have been mixed [5,17].
In line with our results, a hospital-based case–control study by Nagata et al. [17] also found no
association between PPIs and LGIB among users of low-dose aspirin in Japan based on 355 emergency
hospitalizations for LGIB and 8221 non-bleeding control patients. A previous case–control study in
Spain [5] found that among a combined group of users of antiplatelet agents, anti-inflammatory drugs
or anticoagulants, patients using a PPI had a small increased risk of LGIB compared with those not
using a PPI. This study, based on 415 hospitalized cases of LGIB, was underpowered to analyse effects
of PPIs specifically among low-dose aspirin users. Our study had the advantage of including a much
large number of LGIB cases and controls, providing greater power to detect significant differences
between groups. We also did not restrict our study only to hospitalized cases but covered the whole
spectrum of LGIB. This is an important factor in avoiding selection bias because we have previously
shown the majority of LGIB cases among low-dose aspirin users in UK primary care (73%) are referred
to a specialist but are not hospitalized [25].
Our findings, which suggest that PPIs are effective as protective agents against low-dose
aspirin-related UGIB, support several findings from previous reports on the topic [5–7,18,19] yet
further well-designed population-based studies are required to support or refute our findings. Clinical
prescribers should consider prompt PPI co-prescription in these patients because our study also
suggests that delaying PPI use to after the start of low-dose aspirin therapy (e.g., in response to
when a patient presents with abdominal pain or dark blood in their stools) is associated with an
increased risk of UGIB in the few weeks after initiating PPI treatment. This transient risk was not seen
when PPI therapy was started at, or even before, the start of their aspirin therapy. Furthermore, the
risk of gastrointestinal bleeding may be highest during the beginning of low-dose aspirin therapy,
diminishing thereafter [26]. This highlights the importance of timely co-prescription of PPI therapy.
It is not uncommon for patients to discontinue low-dose aspirin if they experience UGIB [27], thus
timely PPI co-prescription could potentially help persistence with therapy. Previous research has
shown that PPI co-prescription per se supports continuation of low-dose aspirin therapy [28], likely
due to the protection against UGIB events and dyspepsia type symptoms. Persistence with low-dose
aspirin therapy is important because its discontinuation has major clinical and economic consequences,
being associated with a significantly increased risk of ischaemic CVD events in secondary prevention
users [29]. Among UGIB/LGIB cases and controls in our study (all of whom were current low-dose
aspirin users), less than a third were using a PPI concomitantly. Clinical guidelines currently advocate
their use in patients with gastrointestinal risk factors [10,30], yet studies in the Netherlands [31] and
Germany [32] suggest that even among this patient population they are under-prescribed. Reasons for
this potential under-prescribing of PPIs are unknown but further research into this would be beneficial,
especially as PPIs may have different effects in different patient subgroups. Older age is an important
risk factor for UGIB [33], and there is evidence from the Oxford Vascular Study [34] that PPIs confer a
greater absolute benefit in terms of UGIB protection among older individuals. Li et al. [34] estimated
that among patients taking aspirin-based antiplatelet treatment for secondary prevention, the number
needed to routinely treat with a PPI to prevent a disabling or fatal UGIB over 5 years was substantially
lower among older individuals—338 for persons less than 65 years, and 25 for those aged 85 years
or more. While it was beyond the scope of our study to evaluate the effect of PPIs among aspirin
users of different age groups, we were able to evaluate the effect among those of another group at
particular high risk of UGIB—users of DAT. Despite the limited power of the analyses and the resulting
wide confidence intervals, our results for DAT suggest that the magnitude of effect might be similar
to that seen among low-dose aspirin users—a 38% reduced the risk of UGIB, in line with a previous
meta-analysis [35]. No association was seen between PPIs and LGIB risk among DAT users, as also
found previously by Nagata et al. [17].
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A key strength of our study is that we provide evidence of the risk of both UGIB and LGIB in
relation to PPI use among low-dose aspirin users from the same study population and time period.
Also, the large sample from a population representative of the UK demographic enabled a large
number of cases and controls to be obtained. Another strength is the use of a suitable comparison
group to evaluate the effect of current PPI use. Because PPI use is a marker of comorbidity per se [36],
the use of past users of PPIs as the reference group (rather than non-users of PPIs) in the logistic
regression analyses means that the effects seen in our study are less likely to be confounded than if
we had used non-users of PPIs as the comparator. We also adjusted for confounders in the analyses,
although we acknowledge that we cannot completely exclude the possibility of residual confounding.
Additionally, some of the sub-group analyses had few exposed cases and controls in the different
strata, resulting in estimates with wide CIs that need to be interpreted cautiously. Of note is that the
frequency of short-term PPI use (a month or less duration) among UGIB/LGIB cases and controls was
small, being even smaller in analyses partitioned by timing, and the confidence limits around the
corresponding estimates were wide. Sample size considerations also limited further analyses according
to gastrointestinal risk factors. Another limitation of our study is the possible misclassification of PPI
use due to the availability of PPIs over-the-counter in the UK. Such misclassification will likely have
been non-differential between cases and controls leading to a small underestimation of the observed
effect in the UGIB analyses.
5. Conclusions
Our results indicate that patients using low-dose aspirin who are co-prescribed a PPI have a
significant 31% reduced risk of UGIB compared with those patients who discontinue PPI therapy, and
do not have an increased risk of LGIB. Timely PPI co-prescription affords greater protection against
UGIB compared with PPI co-therapy that is delayed.
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